A holding company headquartered in USA and China with additional offices in throughout China aims to serve human healthcare and technological development through high-tech investment and real estate investment. Through its investment arm, the firm makes venture investments in healthcare. Typical allocations range from $1-10M in companies from Seed to Series B stages. The firm is open to leading or following in a round. The firm is looking for opportunities from US and Canada that have a China angle.
Additionally, while investing, the firm seeks to leverage their real estate resources in China while investing in companies. This could be through the establishment of a manufacturing plant in China or even starting a joint venture office in China.
Within healthcare, the firm considers biopharmaceuticals, medical devices, diagnostics, and AR/VR/AI innovations in healthcare. The firm is focused on diseases with large market potential including oncology, infectious disease, diabetes, CNS, and cardiovascular diseases. The firm is opportunistic in terms of stage of development and typically participates in Seed to Series B rounds.
The firm is seeking innovative products and can aid with management, operations, and registration. Leveraging its resources in China, the firm can facilitate distribution in the China market. However, distribution rights are not a requirement for investment.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Leave a Reply